Moderna, Merck claim melanoma vaccine halves recurrence risk in Phase III trial

Inside Moderna and Merck’s cancer vaccine triumph

STAT • 24 août 08h35

A phase III study of the mRNA-based melanoma vaccine intismeran autogene showed a statistically significant reduction in the chance of disease recurrence or spread, according to results released by Moderna and Merck.

Moderna and Merck's mRNA Melanoma Vaccine Looks Like a Game Changer

Gizmodo • 20 août 16h15

A Phase 3 trial showed that adding Moderna's personalized mRNA vaccine to Merck's Keytruda immunotherapy extended recurrence-free survival in high-risk melanoma patients.

After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next

Yahoo Finance • 20 août 09h10

Moderna's stock fell 12% in pre-market trading following a 177% jump on news that its mRNA melanoma vaccine met primary endpoints in a Phase 3 trial, prompting mixed reactions from analysts.

mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

Ars Technica • 19 août 16h53

A late-stage study of 1,137 melanoma patients showed that a personalized mRNA vaccine combined with Keytruda extended recurrence-free and distant metastasis-free survival, according to Moderna and Merck.

Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

NBC News • 19 août 14h37

An mRNA-based personalized vaccine combined with Merck's Keytruda showed interim evidence of extending disease-free time for high-risk melanoma patients, according to a company release.